Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. The presentation will focus on the company's development of induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer. A recording will be available on their website starting March 30 at 7:00 AM ET for 90 days. Century's innovative approach seeks to advance cancer care by leveraging adult stem cells and genetic engineering.
- None.
- None.
PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference, being held virtually on March 30, 2022.
A recording of the presentation will be available on March 30, 2022 at 7:00 AM ET on the Events & Presentations section of Century’s website and will be available for 90 days.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com.
Century Therapeutics Forward-Looking Statement
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Company: Elizabeth Krutoholow – investor.relations@centurytx.com
Investors: Melissa Forst/Maghan Meyers – century@argotpartners.com
Media: Joshua R. Mansbach – century@argotpartners.com
FAQ
What is the date of Century Therapeutics' presentation at the H.C. Wainwright Conference?
Where can I access the recording of Century Therapeutics' conference presentation?
What innovative therapies is Century Therapeutics developing?
What cancer types is Century Therapeutics targeting with its therapies?
What is the stock symbol for Century Therapeutics?
